Abstract
In this study, we developed a simple, solvent- and metal-free one-pot method to synthesize 4-acyl-1,2,3-triazoles from readily available acetophenones and various aryl azides. Thirty-three compounds were obtained with yields ranging from 40 to 82 % within 2 h under thermal conditions. This research also investigates these compounds as precursors to bioactive hydroxy‑1,2,3-triazoles, aiming to identify new drug candidates for Cystic Fibrosis (CF) treatment. Specifically, we evaluated their ability to rescue the common CF-causing variant p.Phe508del-CFTR. Two new compounds, LSO-162 and LSO-168, successfully rescued p.Phe508del-CFTR trafficking with EC50 values of 2.41 and 1.91 µM, respectively. For comparison, the clinically approved drug VX-445, a compound in a triple combination therapy, has an EC50 of 0.245 µM. Computational studies provided insights into the structure-activity relationship, particularly the role of carbonylated and hydroxylated triazole-based compounds as potential new p.Phe508del-CFTR traffic correctors. These findings highlight the potential for developing new, effective CF treatments.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call